SOPs for Drug Discovery

The purpose of this Standard Operating Procedure (SOP) is to outline the process for conducting ADME (Absorption, Distribution, Metabolism, and Excretion) screening during the early stages of drug discovery. ADME screening is crucial for evaluating the pharmacokinetic properties of potential drug candidates to determine their suitability for further development. This SOP ensures that ADME screening is conducted systematically and effectively to assess the drug-likeness of lead compounds and identify potential candidates for optimization.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process of pharmacophore modeling in drug discovery. Pharmacophore modeling is a computational technique used to identify the essential chemical features required for a molecule to interact with a specific biological target. The aim is to design or screen for compounds that contain the key pharmacophoric features for binding to a target, thereby facilitating the identification of new drug candidates. This SOP ensures that pharmacophore modeling is conducted systematically and efficiently, using validated tools and methods to identify and optimize lead compounds.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process of selecting molecular scaffolds in drug discovery. Molecular scaffolds serve as the core structure of drug molecules and are critical in the design of novel compounds with desired biological activity. This SOP ensures that scaffold selection is carried out systematically, using both computational and experimental approaches to identify scaffolds with optimal properties for lead optimization and further drug development.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process of lead optimization in drug discovery. Lead optimization is the phase in drug development where the chemical structure of lead compounds is modified to improve their potency, selectivity, pharmacokinetic properties, and overall drug-likeness. This SOP ensures that lead optimization is carried out systematically, with appropriate computational tools, experimental validation, and consideration of regulatory guidelines to identify the best candidates for clinical development.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process for identifying and prioritizing hits during the drug discovery process. Hit identification is a critical step where compounds that exhibit desired biological activity against a specific target are selected from large compound libraries or screening assays. Prioritization ensures that the most promising candidates are advanced for further development and optimization. This SOP ensures that hit identification and prioritization are conducted in a consistent, reproducible, and systematic manner to support efficient drug discovery efforts.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for preparing and maintaining compound libraries used in drug discovery. Compound libraries are essential resources for screening and identifying potential drug candidates. This SOP ensures that compound libraries are well-organized, properly maintained, and ready for high-throughput screening (HTS) or other screening methods, facilitating the efficient identification of novel drug leads.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process of applying Structure-Based Drug Design (SBDD) in drug discovery. SBDD is a computational method that uses the 3D structure of a target protein or nucleic acid to design molecules that can interact with the target, modulate its activity, and ultimately lead to the development of therapeutic drugs. This SOP ensures that SBDD is conducted efficiently, using validated computational techniques and experimental validation to identify lead compounds for further development.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process of applying Fragment-Based Drug Design (FBDD) in drug discovery. FBDD is a computational and experimental approach used to identify small molecule fragments that can bind to a biological target, which can then be elaborated into lead compounds. This SOP ensures that FBDD is conducted systematically, utilizing appropriate techniques, software tools, and experimental validations to identify fragments with high binding affinity and potential for drug development.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process of applying Quantitative Structure-Activity Relationship (QSAR) modeling in drug discovery. QSAR modeling is a computational method used to predict the biological activity of chemical compounds based on their molecular structure. This SOP ensures that QSAR modeling is conducted systematically, using reliable data and computational techniques, to support the identification and optimization of lead compounds in drug development.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process for conducting in silico docking studies in drug discovery. In silico docking is a computational technique used to predict the binding interactions between small molecules and a target protein or nucleic acid. This SOP ensures that docking studies are conducted systematically, with appropriate software tools, and using accurate structural data to identify potential drug candidates for further experimental validation.
Click to read the full article.